跳至主要内容
临床试验/NCT01040585
NCT01040585撤回不适用

Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America

Pfizer0 个研究点开始时间: 2010年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
发起方
Pfizer
主要终点
The rate of resistance Empirical treatment days before specific therapy. Treatment days with Linezolid. Treatment days with Vancomycin.

研究概览

简要总结

The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Evidence of a legally acceptable representative signed and dated informed consent document indicating that him or her has been informed of all pertinent aspects of the study.
  • Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on ICU with LIN or VAN; on the selected institutions.

排除标准

  • Adult men or women with nosocomial pneumonia not associated to a ventilator.

研究组 & 干预措施

Central America and the Caribbean

Panama, Costa Rica, Honduras, El Salvador and Nicaragua

干预措施: Linezolid (Drug)

结局指标

主要结局

The rate of resistance Empirical treatment days before specific therapy. Treatment days with Linezolid. Treatment days with Vancomycin.

时间窗: 4 months

Rate of renal failure.

时间窗: 4 months

Rate of healing with Linezolid.

时间窗: 4 months

Rate of healing with Vancomycin.

时间窗: 4 months

次要结局

  • Hospitalization days average with VAN and Linezolid.(4 months)
  • Variation of prices and values among the different institutions.(4 months)
  • The average costs of each intervention.(4 months)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

相似试验